These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Scheen AJ Diabetes Metab; 1998 Sep; 24(4):311-20. PubMed ID: 9805641 [TBL] [Abstract][Full Text] [Related]
24. Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects. Standl E Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S121-2. PubMed ID: 14502110 [TBL] [Abstract][Full Text] [Related]
25. Therapy for type 2 diabetes: where do we stand after the UK prospective diabetes study? Lopez-Liuchi JV; Meier CA Eur J Endocrinol; 1999 Jan; 140(1):4-6. PubMed ID: 10037243 [No Abstract] [Full Text] [Related]
26. Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus. Galligan A; Greenaway TM Intern Med J; 2016 May; 46(5):540-9. PubMed ID: 27170238 [TBL] [Abstract][Full Text] [Related]
27. From the World Congress of Cardiology, Barcelona, 2006--Support for wider metformin usage in type 2 diabetes. Cardiovasc J S Afr; 2006; 17(5):267. PubMed ID: 17117236 [No Abstract] [Full Text] [Related]
28. Short-term effects of metformin in type 2 diabetes. Eriksson A; Attvall S; Bonnier M; Eriksson JW; Rosander B; Karlsson FA Diabetes Obes Metab; 2007 Jul; 9(4):483-9. PubMed ID: 17587390 [TBL] [Abstract][Full Text] [Related]
29. Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. Davidson JA; Scheen AJ; Howlett HC Drug Saf; 2004; 27(15):1205-16. PubMed ID: 15588116 [TBL] [Abstract][Full Text] [Related]
30. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000 [TBL] [Abstract][Full Text] [Related]
32. Metformin: an antihyperglycemic agent for treatment of type II diabetes. Melchior WR; Jaber LA Ann Pharmacother; 1996 Feb; 30(2):158-64. PubMed ID: 8835050 [TBL] [Abstract][Full Text] [Related]
33. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Howlett HC; Bailey CJ Drug Saf; 1999 Jun; 20(6):489-503. PubMed ID: 10392666 [TBL] [Abstract][Full Text] [Related]
34. A primary care register for impaired glucose handling (IGH): impact on cardiometabolic profile. Heald AH; Knapman H; Nair S; Chambers T; Radford D; Rushton T; Anderson SG Prim Care Diabetes; 2012 Oct; 6(3):213-9. PubMed ID: 22560663 [TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg. Zimmet P; Collier G Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521 [TBL] [Abstract][Full Text] [Related]
36. Antipsychotic drug-treated patients best suited for metformin therapy. Hasnain M; Vieweg WV Acta Psychiatr Scand; 2013 Dec; 128(6):488-9. PubMed ID: 23659558 [No Abstract] [Full Text] [Related]